Myoferlin (MYOF), as a member of the ferlin family, is a type II transmembrane protein with
a single transmembrane domain at the carbon terminus. Studies have shown that MYOF is involved in
pivotal physiological functions related to numerous cell membranes, such as extracellular secretion, endocytosis
cycle, vesicle trafficking, membrane repair, membrane receptor recycling, and secreted protein
efflux. Recently, the studies have also revealed that MYOF is overexpressed in a variety of cancers such
as colorectal cancer, pancreatic cancer, breast cancer, melanoma, gastric cancer, and non-small-cell lung
cancer. High expression of MYOF is associated with the high invasion of tumors and poor clinical prognosis.
MYOF medicates the expression, secretion, and distribution of proteins, which were closely related
to cancers, as well as the energy utilization of cancer cells, lipid metabolism and other physiological
activities by regulating the physiological processes of membrane transport. In this short article, we
briefly summarize the latest progress related to MYOF, indicating that small molecule inhibitors targeting
the MYOF-C2D domain can selectively inhibit the proliferation and migration of cancer cells, and
MYOF may be a promising target for the treatment of malignant tumors.